Dr. Uli Broedl, MD, is Corporate Senior Vice President and Head of Global Clinical Development & Operations at Boehringer Ingelheim. He is passionate about research, development and digital innovation to improve patient access and care. He steers Boehringer Ingelheim’s global Medicine Excellence Transformation to accelerate Clinical Development timelines and to create holistic Clinical Development stakeholder (regulator-payer-patient) evidence, a comprehensive global approach integrating people&culture, digital and business transformation initiatives.

Dr. Broedl held various leadership roles at Boehringer Ingelheim over the last 14 years, including Global Head of Late Clinical Development of Boehringer Ingelheim’s diabetes portfolio (with successful development and approval of the SGLT2 inhibitor empagliflozin (Jardiance) to improve glycemic control and to reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus), Country Medical Director Canada, and Head of Global Clinical Operations.

Dr. Broedl is adjunct Professor of Medicine at the University of Munich, Germany, and holds a Doctorate of Medicine degree from the University of Munich. He completed a Postdoctoral Fellowship in Dr. Daniel J. Rader´s lab, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, USA, and completed his training in Internal Medicine, Endocrinology and Metabolism at the Medical Center of the University of Munich. He published more than 100 scientific articles in peer-reviewed journals with >30000 citations (google scholar) and an h-index of 56 (Scopus).